시장보고서
상품코드
1429497

세계의 HIV 치료제 시장 보고서(2024년)

HIV Drugs Global Market Report 2024

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 175 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

HIV 치료제 시장 규모는 향후 몇 년 동안 꾸준히 성장할 것으로 예상됩니다. 2028년에는 연평균 성장률(CAGR) 3.9%로 412억 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 정부의 지원 및 노력 강화, 의료비 증가, HIV 연구 및 개발 지출 증가, HIV 감염률 증가, 인식 증가, 신흥 시장의 경제 성장에 기인하는 것으로 보입니다. 예측 기간 동안 예상되는 주요 동향으로는 3D 바이오프린팅 기술에 대한 투자, 신제품 개발 혁신, HIV 치료를 위한 다제 병용 제품 개발, 전략적 제휴 및 협약 추구 등이 있습니다.

세계 HIV 치료제 시장은 신종 코로나바이러스 감염증(COVID-19) 확산으로 인해 성장세를 보이고 있습니다. HIV 치료제는 COVID-19 감염과 싸우기 위해 재사용되고 있으며, 리토나비어 강화 로피나비어(LPV/r)와 같은 항레트로바이러스 약물이 여러 국가에서 COVID-19 감염 치료를 위해 평가 및 사용되고 있습니다.

HIV 질환의 진단과 치료에 대한 사람들의 인식이 높아지면서 HIV 치료제 시장의 성장을 촉진하는 데 중요한 역할을 하고 있습니다. HIV/AIDS는 가장 만성적인 질병 중 하나이며, 높은 유병률로 인해 전 세계적으로 큰 주목을 받고 있습니다. 예를 들어, 2023년 5월 미국 미네소타주 보건국의 보고서에 따르면 2021년에는 새로 진단된 HIV 감염 사례가 8% 증가하여 총 298건에 달할 것으로 예상했습니다. 협회는 HIV 예방, 치료 및 관리에 대한 지역 사회의 인식을 높이기 위해 수많은 노력과 교육 캠페인을 도입했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

  • 고인플레이션이 시장에 미치는 영향
  • 우크라이나·러시아 전쟁이 시장에 미치는 영향
  • COVID-19에 의한 시장에 대한 영향

제5장 세계 시장 규모와 성장

  • 세계의 시장 성장 촉진요인과 억제요인
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
  • 세계의 시장 규모 실적과 성장, 2018-2023년
  • 세계의 시장 규모 예측과 성장, 2023-2028년, 2033년

제6장 시장 세분화

  • 세계의 HIV 치료제 시장, 유형별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 뉴클레오시드 역전사효소 억제제(NRT)
  • 비뉴클레오시드계 역전사효소 억제제(NNRT)
  • 프로테아제 억제제
  • 통합 억제제
  • 융합 억제제
  • 케모카인 수용체 억제제
  • 기타 유형
  • 세계의 HIV 치료제 시장, 투여별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 경구
  • 비경구
  • 세계의 HIV 치료제 시장, 용도별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 병원 약국
  • 소매 약국
  • 온라인 약국
  • 기타 용도

제7장 지역 및 국가 분석

  • 세계의 HIV 치료제 시장, 지역별, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 세계의 HIV 치료제 시장, 국가별, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 상황과 기업 개요

  • HIV 치료제 시장 경쟁 상황
  • HIV 치료제 시장 기업 개요
    • Gilead Sciences Inc.
    • GlaxoSmithKline plc.
    • Johnson &Johnson
    • Merck &Co. Inc.
    • Boehringer Ingelheim International GmbH

제31장 기타 주요 및 혁신적인 기업

  • Cipla
  • Aurobindo Pharma
  • AbbVie
  • Mylan NV
  • Emcure Pharmaceuticals
  • Micro Labs Limited
  • Northeast Pharmaceutical Group Co. Ltd
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd
  • Strides Arcolab Limited
  • Hetero Labs Limited
  • Shanghai Desano Bio-pharmaceutical Co.
  • Anhui Biochem Biopharmaceutical Co. Ltd.
  • China's National Health Commission(NHC)
  • Shanghai Xinxing Medicine Co. Ltd

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병

제35장 향후 전망과 가능성 분석

제36장 부록

ksm 24.03.21

HIV drugs, also known as antiretroviral drugs, are commonly employed for the treatment of HIV. These medications play a crucial role in inhibiting the human immunodeficiency virus (HIV) or other retroviruses within the body, preventing their proliferation. Without treatment, HIV can lead to acquired immunodeficiency syndrome (AIDS), and while there is currently no highly effective cure, these drugs are essential in managing the condition.

The primary categories of HIV drugs include nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors, integrase inhibitors, fusion inhibitors, chemokine receptor inhibitors, and other variations. Nucleoside reverse transcriptase inhibitors (NRTIs) are structural nucleoside analogs of DNA nucleotides designed to hinder HIV-1 RT and impede viral replication by preventing the reverse transcription of the HIV genome. These drugs are typically administered through oral and parenteral methods and are made available through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others.

The HIV drugs market research report is one of a series of new reports from The Business Research Company that provides HIV drugs market statistics, including HIV drugs industry global market size, regional shares, competitors with an HIV drugs market share, detailed HIV drugs market segments, market trends and opportunities, and any further data you may need to thrive in the HIV drugs industry. This HIV drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hiv drugs market size has grown steadily in recent years. It will grow from $33.82 billion in 2023 to $35.33 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%. The growth observed in the historical period can be ascribed to heightened government support and initiatives, an upswing in healthcare expenditure, an increase in spending on HIV research and development, a rise in the incidence of HIV infections, heightened awareness, and economic growth in emerging markets.

The hiv drugs market size is expected to see steady growth in the next few years. It will grow to $41.2 billion in 2028 at a compound annual growth rate (CAGR) of 3.9%. The anticipated growth in the forecast period can be credited to heightened government support and initiatives, an upswing in healthcare expenditure, increased spending on HIV research and development, a rise in the incidence of HIV infections, heightened awareness, and economic growth in emerging markets. Major trends expected in the forecast period include the investment in 3D bioprinting technology, innovations in new product development, the creation of multi-class combination products for HIV treatment, and the pursuit of strategic collaborations and agreements.

The global HIV drug market has experienced growth, fueled by the novel COVID-19 outbreak. HIV drugs are being repurposed to combat COVID-19 infections, with antiretroviral drugs such as lopinavir boosted with ritonavir (LPV/r) being evaluated and used in several countries for treating COVID-19 infections.

The increased awareness among people regarding the diagnosis and treatment of HIV disease plays a crucial role in propelling the growth of the HIV drug market. HIV/AIDS, being one of the most chronic diseases, has garnered significant awareness worldwide due to its high prevalence. For example, in May 2023, a report from the Minnesota Department of Health, a US-based state health agency, indicated an 8% increase in reported instances of newly diagnosed HIV infections, totaling 298 cases in 2021. Various federal government agencies and global associations have introduced numerous initiatives and education campaigns to raise community awareness about HIV prevention, treatment, and care.

The anticipated increase in government spending is poised to drive the growth of the HIV drugs market in the future. Government spending, also referred to as public spending or government expenditure, encompasses the total funds allocated by a government to finance its various functions, programs, and services. Elevated government funding contributes to diverse aspects of the HIV drug market, spanning research and development, enhancing access and awareness, and mitigating the societal and economic impact of the disease. Such investments play a pivotal role in fostering the market's expansion and overall efficacy in combating the HIV or AIDS pandemic. As an illustration, in March 2023, the US government's Budget of the U.S. Government report revealed that Joe Biden's Fiscal Year (FY) 2024 budget proposal allocated $850 million in funding for the CDC, HRSA, IHS, and NIH to support and expand the implementation of the Ending the HIV Epidemic in the U.S. initiative. This marked a substantial increase of $277 million (48%) compared to the funding level enacted in FY23. Hence, increased government spending is a driving force behind the growth of the HIV drug market.

The antiretroviral drugs market is increasingly adopting multi-class combination products for antiretroviral therapy. Multi-class combination drugs consolidate multiple medications into a single drug form. Examples of such drugs or single-tablet regimens (STRs) encompass both NRTIs and NNRTIs, such as doravirine, lamivudine, and tenofovir disoproxil fumarate (Delstrigo). The segmentation of drugs based on drug class includes Integrase Inhibitors, Protease Inhibitors, Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), and Others. The rise in the burden of HIV and new drug approvals propels the use of multi-class combination products. According to WHO, in 2021, 1.5 million [1.1-2.0 million] people contracted HIV, and 650,000 [510,000-860,000] people died from HIV-related causes. Many companies are prioritizing the development of innovative products for the treatment of HIV through antiretroviral drugs to maintain their competitive edge and expand into new regional markets.

Major companies in the HIV drugs market are innovating by introducing new products, such as drugs for multi-drug resistant HIV, aiming to cater to larger customer bases, increase sales, and boost revenue. Drugs for multi-drug resistant HIV (MDR-HIV) are designed specifically to treat HIV infections in individuals who have developed resistance to multiple classes of antiretroviral drugs. As an example, in December 2022, Gilead Sciences Inc., a US-based pharmaceutical company, announced FDA approval for Sunlenca (lenacapavir). This medication, with a multi-stage mode of action, distinguishes itself from recently approved antiviral agent classes. It has no known in vitro cross-resistance to other existing medication classes. Sunlenca provides a new, twice-yearly therapy option for adults with HIV not adequately controlled by their current medication regimen. Lenacapavir serves as the foundation for Gilead's upcoming HIV treatments, offering a range of long-acting options to accommodate individual needs and preferences, potentially maximizing outcomes and reducing the burden of care.

Major companies operating in the hiv drugs market report are Gilead Sciences Inc., GlaxoSmithKline plc., Johnson & Johnson, Merck & Co. Inc., Boehringer Ingelheim International GmbH, Cipla, Aurobindo Pharma, AbbVie, Mylan N.V., Emcure Pharmaceuticals, Micro Labs Limited, Northeast Pharmaceutical Group Co. Ltd., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Strides Arcolab Limited, Hetero Labs Limited, Shanghai Desano Bio-pharmaceutical Co., Anhui Biochem Biopharmaceutical Co. Ltd., China's National Health Commission (NHC), Shanghai Xinxing Medicine Co. Ltd., China Meheco Xinxing Pharma Co. Ltd., CytoDyn Inc., Janssen Pharmaceutical, Bavarian Nordic, Roche Laboratories, Pharmstandard, Pharmasyntez, R-Pharm, Alium, ChemRar Group, Gritstone Oncology, Enzolytics Inc., BioClonetics Immunotherapeutics Inc., Dewpoint Therapeutics, Lyndra Therapeutics, Mylan N.V., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Teva Canada, ViiV Healthcare Canada, Alfa Rio Quimica Ltda., Globe Quimica S/A, Nortec Quimica S.A., AstraZeneca, Zion Medical, GSK, Abbott Laboratories, Aspen Pharmacare Limited, Pharmacare Ltd.

North America was the largest region in the HIV drugs market share in 2023. Middle East is expected to be the largest growing region in the global HIV drug market during the forecast period. The regions covered in the hiv drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hiv drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The HIV drug market consists of sales of Tivicay, Triumeq, Truvada, and Vemlidy. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

HIV Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hiv drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hiv drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hiv drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Nucleoside Reverse Transcriptase Inhibitors (NRT's); Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's); Protease Inhibitors; Integrase strand transfer inhibitors (INSTIs); Other Types
  • 2) By Administration: Oral; Parenteral
  • 3) By Application: Hospital Pharmacies; Retail Pharmacies; Other Applications
  • Companies Mentioned: Gilead Sciences Inc.; GlaxoSmithKline plc.; Johnson & Johnson; Merck & Co. Inc.; Boehringer Ingelheim International GmbH
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. HIV Drugs Market Characteristics

3. HIV Drugs Market Trends And Strategies

4. HIV Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global HIV Drugs Market Size and Growth

  • 5.1. Global HIV Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global HIV Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global HIV Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. HIV Drugs Market Segmentation

  • 6.1. Global HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Nucleoside Reverse Transcriptase Inhibitors (NRT's)
  • Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's)
  • Protease Inhibitors
  • Integrate Inhibitors
  • Fusion Inhibitors
  • Chemokine Receptor Inhibitors
  • Other Types
  • 6.2. Global HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
  • 6.3. Global HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Applications

7. HIV Drugs Market Regional And Country Analysis

  • 7.1. Global HIV Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global HIV Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific HIV Drugs Market

  • 8.1. Asia-Pacific HIV Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China HIV Drugs Market

  • 9.1. China HIV Drugs Market Overview
  • 9.2. China HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India HIV Drugs Market

  • 10.1. India HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan HIV Drugs Market

  • 11.1. Japan HIV Drugs Market Overview
  • 11.2. Japan HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia HIV Drugs Market

  • 12.1. Australia HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia HIV Drugs Market

  • 13.1. Indonesia HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea HIV Drugs Market

  • 14.1. South Korea HIV Drugs Market Overview
  • 14.2. South Korea HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe HIV Drugs Market

  • 15.1. Western Europe HIV Drugs Market Overview
  • 15.2. Western Europe HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK HIV Drugs Market

  • 16.1. UK HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany HIV Drugs Market

  • 17.1. Germany HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France HIV Drugs Market

  • 18.1. France HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy HIV Drugs Market

  • 19.1. Italy HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain HIV Drugs Market

  • 20.1. Spain HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe HIV Drugs Market

  • 21.1. Eastern Europe HIV Drugs Market Overview
  • 21.2. Eastern Europe HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia HIV Drugs Market

  • 22.1. Russia HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America HIV Drugs Market

  • 23.1. North America HIV Drugs Market Overview
  • 23.2. North America HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA HIV Drugs Market

  • 24.1. USA HIV Drugs Market Overview
  • 24.2. USA HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada HIV Drugs Market

  • 25.1. Canada HIV Drugs Market Overview
  • 25.2. Canada HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America HIV Drugs Market

  • 26.1. South America HIV Drugs Market Overview
  • 26.2. South America HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil HIV Drugs Market

  • 27.1. Brazil HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East HIV Drugs Market

  • 28.1. Middle East HIV Drugs Market Overview
  • 28.2. Middle East HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa HIV Drugs Market

  • 29.1. Africa HIV Drugs Market Overview
  • 29.2. Africa HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. HIV Drugs Market Competitive Landscape And Company Profiles

  • 30.1. HIV Drugs Market Competitive Landscape
  • 30.2. HIV Drugs Market Company Profiles
    • 30.2.1. Gilead Sciences Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. GlaxoSmithKline plc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Johnson & Johnson
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Merck & Co. Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Boehringer Ingelheim International GmbH
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. HIV Drugs Market Other Major And Innovative Companies

  • 31.1. Cipla
  • 31.2. Aurobindo Pharma
  • 31.3. AbbVie
  • 31.4. Mylan N.V.
  • 31.5. Emcure Pharmaceuticals
  • 31.6. Micro Labs Limited
  • 31.7. Northeast Pharmaceutical Group Co. Ltd
  • 31.8. Dr. Reddy's Laboratories Ltd.
  • 31.9. Sun Pharmaceutical Industries Ltd
  • 31.10. Strides Arcolab Limited
  • 31.11. Hetero Labs Limited
  • 31.12. Shanghai Desano Bio-pharmaceutical Co.
  • 31.13. Anhui Biochem Biopharmaceutical Co. Ltd.
  • 31.14. China's National Health Commission (NHC)
  • 31.15. Shanghai Xinxing Medicine Co. Ltd

32. Global HIV Drugs Market Competitive Benchmarking

33. Global HIV Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The HIV Drugs Market

35. HIV Drugs Market Future Outlook and Potential Analysis

  • 35.1 HIV Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 HIV Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 HIV Drugs Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제